Hims & Hers Expands to Canada with Weight Loss Focus
US telehealth giant Hims & Hers enters Canadian market through Livewell acquisition, targeting obesity crisis with affordable digital healthcare and upcoming generic semaglutide access.
/ 44 items
#NVO↓
Novo Nordisk Stock Plunges 10% as Ozempic Fails Alzheimer's Trial
Novo Nordisk shares tumbled 10% after Ozempic failed to slow Alzheimer's progression in clinical trials, marking another setback for the struggling Danish drugmaker against rival Eli Lilly.
LifeMD Shares Tumble on Earnings Miss and GLP-1 Market Struggles
LifeMD stock plunged 25% after missing Q3 earnings and cutting guidance, citing fierce competition from low-cost compounded GLP-1 weight loss drugs despite Novo and Lilly partnerships.
Citi Surprised by Hims Exclusion as Novo Cuts GLP-1 Prices
Citi analyst Daniel Grosslight says competition is increasing in weight-loss drug pricing after Novo Nordisk introduced a $199 monthly offer for Wegovy and Ozempic, leaving out Hims & Hers as a distribution partner.
LifeMD Offers Lowest Cash-Pay Price for Wegovy & Ozempic at $199/Month
LifeMD now provides the lowest nationwide cash-pay price for Wegovy and Ozempic at $199/month for new patients, supporting more affordable access to GLP-1 weight-loss treatments.
Novo Nordisk, Eli Lilly Deny Mangoceuticals Partnership
Novo Nordisk and Eli Lilly reject Mangoceuticals' false partnership claims regarding weight-loss drugs.